Literature DB >> 27600276

Diabetic cardiomyopathy: a clinical entity or a cluster of molecular heart changes?

Maria Mizamtsidi1, Stavroula A Paschou1, Julia Grapsa2, Andromachi Vryonidou3.   

Abstract

BACKGROUND: Although the increasing rate of cardiovascular mortality in patients with diabetes is thought to be due to the coronary atherosclerosis caused mainly by compounding factors such as dyslipidaemia and hypertension, it is now well documented that diabetes alone can lead to a vast array of molecular changes in the heart.
DESIGN: The aim of this article was to comprehensively review the pathophysiological and molecular changes leading to diabetic cardiomyopathy (DCM), as well as to critically analyse the literature that offers evidence in favour and against the existence of the overt clinical expression of this entity.
RESULTS: We included in the discussion studies that have revealed the existence of diabetic cardiomyopathy with unique remodelling pattern when compared to other types of cardiomyopathies. On the other hand, several studies debate the existence of clinically discernible cardiomyopathy caused only by diabetes and were also presented and discussed in details.
CONCLUSION: Clinicians should be aware of DCM when facing patients with diabetes in order both to recognize on time relevant symptoms and to intensively look for and treat other compounding factors, apart from optimal glucose control. Furthermore, the elucidation of the pathophysiological mechanisms leading to DCM could provide new therapeutic targets for heart disease, which will be wonderful for the good of our patients.
© 2016 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Cardiomyopathy; cardiovascular; diabetes; hyperglycemia; myocardium; oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 27600276     DOI: 10.1111/eci.12673

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  24 in total

1.  (Pro)renin receptor-mediated myocardial injury, apoptosis, and inflammatory response in rats with diabetic cardiomyopathy.

Authors:  Xuefei Dong; Shiran Yu; Ying Wang; Min Yang; Jie Xiong; Naier Hei; Bo Dong; Qing Su; Jing Chen
Journal:  J Biol Chem       Date:  2019-04-05       Impact factor: 5.157

2.  Asymptomatic type 2 diabetes mellitus display a reduced myocardial deformation but adequate response during exercise.

Authors:  Lisa Van Ryckeghem; Charly Keytsman; Elvire Verbaanderd; Ines Frederix; Elise Bakelants; Thibault Petit; Siddharth Jogani; Sarah Stroobants; Paul Dendale; Virginie Bito; Jan Verwerft; Dominique Hansen
Journal:  Eur J Appl Physiol       Date:  2021-01-08       Impact factor: 3.078

3.  CELF1 contributes to aberrant alternative splicing patterns in the type 1 diabetic heart.

Authors:  KarryAnne Belanger; Curtis A Nutter; Jin Li; Sadia Tasnim; Peiru Liu; Peng Yu; Muge N Kuyumcu-Martinez
Journal:  Biochem Biophys Res Commun       Date:  2018-08-27       Impact factor: 3.575

Review 4.  Pathological Effects of Exosomes in Mediating Diabetic Cardiomyopathy.

Authors:  Esam S B Salem; Guo-Chang Fan
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

5.  Tanshinone IIA improves diabetes mellitus via the NF-κB-induced AMPK signal pathway.

Authors:  Feng-Yi Yuan; Min Zhang; Ping Xu; Dan Xu; Ping Chen; Min Ren; Qin Sun; Jing-Yan Chen; Juan Du; Xia-Lian Tang
Journal:  Exp Ther Med       Date:  2018-09-03       Impact factor: 2.447

Review 6.  Evidence for human diabetic cardiomyopathy.

Authors:  Claudio Napoli; Giuseppe Paolisso; Raffaele Marfella; Celestino Sardu; Gelsomina Mansueto
Journal:  Acta Diabetol       Date:  2021-03-31       Impact factor: 4.280

7.  Diabetic retinopathy is associated with diastolic dysfunction in type 2 diabetic patients with non-ischemic dilated cardiomyopathy.

Authors:  Yoo-Ri Chung; Se-Jun Park; Ka Young Moon; Seoyoung Annie Choi; Hong-Seok Lim; Sung Wook Park; Jeong Hun Kim; Kihwang Lee
Journal:  Cardiovasc Diabetol       Date:  2017-07-06       Impact factor: 9.951

8.  The association of long-term glycaemic variability versus sustained chronic hyperglycaemia with heart rate-corrected QT interval in patients with type 2 diabetes.

Authors:  Jian-Bin Su; Xiao-Hua Yang; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Li-Hua Zhao; Feng Xu; Tong Chen; Xing-Bo Cheng; Xue-Qin Wang; Yan Lu
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

9.  Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.

Authors:  Alexander J M Brown; Chim Lang; Rory McCrimmon; Allan Struthers
Journal:  BMC Cardiovasc Disord       Date:  2017-08-23       Impact factor: 2.298

10.  Mechanisms underlying diabetic cardiomyopathy: From pathophysiology to novel therapeutic targets.

Authors:  Shuo Cong; Chrishan J A Ramachandra; Kp Myu Mai Ja; Jonathan Yap; Winston Shim; Lai Wei; Derek J Hausenloy
Journal:  Cond Med       Date:  2020-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.